Editorial Commentary:Adherence to Antiretroviral Therapy: How Much Is Enough?

This publication has 18 references indexed in Scilit:

• Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral Suppression
  Clinical Infectious Diseases, 2006
• Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors
  Clinical Infectious Diseases, 2005
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004
• A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection
  The Journal of Infectious Diseases, 2004
• Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
  New England Journal of Medicine, 2004
• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients
  AIDS, 2004
• Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
  The Journal of Infectious Diseases, 2004
• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
  New England Journal of Medicine, 2002
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
  AIDS, 1997